Karl S. Peggs

Karl S. Peggs

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 145 publications

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".

Journal: Haematologica
Published: August 01, 2026

Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group.

Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group.

Journal: The Lancet. Haematology
Published: April 25, 2026

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

Journal: The Lancet. Haematology
Published: February 03, 2026

Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody Development.

Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody Development.

Journal: Annual review of medicine
Published: November 13, 2025

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies.

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies.

Journal: Immunity
Published: May 30, 2025

Tumor-Infiltrating Clonal Hematopoiesis.

Tumor-Infiltrating Clonal Hematopoiesis.

Journal: The New England journal of medicine
Published: April 23, 2025

A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL.

A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL.

Journal: Molecular therapy. Advances
Published: February 13, 2025

Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion.

Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion.

Journal: Blood
Published: February 10, 2025

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

Journal: The New England journal of medicine
Published: November 27, 2024

Human herpesvirus 6 and CAR T-cell toxicity.

Human herpesvirus 6 and CAR T-cell toxicity.

Journal: Blood
Published: August 01, 2024

The Effect of the Pre-Transplant Disease Status on the Outcome for Recipients of T-Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell Lymphomas.

The Effect of the Pre-Transplant Disease Status on the Outcome for Recipients of T-Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell Lymphomas.

Journal: European journal of haematology
Published: July 31, 2024

COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experience.

COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experience.

Journal: Leukemia research
Published: July 28, 2024
Showing 1-12 of 145

Last Updated: 09/26/2026